Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty
Anemia, Arthritis, Total Knee Arthroplasty
About this trial
This is an interventional treatment trial for Anemia
Eligibility Criteria
Inclusion Criteria:
- older than 18 years
- scheduled for a primary cemented TKA or cementless THA
- preoperative hematocrit less than 36%
Exclusion Criteria:
- Known allergy to TXA
- acquired disturbances of color vision
- refusal of blood products
- pre-operative use of anticoagulant therapy within five days before surgery
- a history of arterial or venous thrombotic disease (including a history of Deep Vein Thrombosis, Pulmonary Embolus, Cerebrovascular accident or Transient ischemic attack)
- pregnancy, breastfeeding
- major co-morbidities (myocardial infarction or stent placement within one year, severe pulmonary disease, renal impairment, or hepatic failure)
- undergoing a revision TKA, revision THA, hip resurfacing, or Unicompartmental Knee Arthroplasty
- younger than 18 years old
- decline to participate
Sites / Locations
- Rush University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Experimental
Experimental
Conventional Oral TXA, Total Hip Arthroplasty (THA)
Conventional Oral TXA, Total Knee Arthroplasty (TKA)
Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)
Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)
THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.